NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
September 23 2024 - 6:47PM
Business Wire
Company will host business update call on Sept.
24, 2024, at 8:30 a.m. ET
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology
testing services company, today issued the following statement in
response to inquiries:
NeoGenomics has cleared the feasibility stage with a new version
of its RaDaR® technology and has resolved litigation with Natera
regarding RaDaR 1.0. The Company will host a business update
conference call and webcast on Tuesday, Sept. 24, 2024, beginning
at 8:30 a.m. Eastern Time.
The accelerated progress of the new RaDaR technology provided
the Company the opportunity to negotiate a resolution with Natera
as to RaDaR 1.0. The settlement, while confidential, is not
material to the Company’s bottom line and does not impact its
adjusted EBITDA guidance range or liquidity expectations.
The live webcast may be accessed by visiting the Investor
Relations section of our website at ir.neogenomics.com. The webcast
will be archived and available for replay shortly after the
conclusion of the call.
To access the live call via telephone, dial (877) 545-0523
(domestic) or (973) 528-0016 (international) at least five minutes
prior to the call. The participant access code is 196876.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and
information services, providing one of the most comprehensive
oncology-focused testing menus in the world for physicians to help
them diagnose and treat cancer. The Company's Pharma Services
Division serves pharmaceutical clients in clinical trials and drug
development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP
accredited and CLIA certified laboratories for full-service sample
processing in Fort Myers, Florida; Aliso Viejo and San Diego,
California; Research Triangle Park, North Carolina; and Houston,
Texas; and a CAP accredited full-service, sample-processing
laboratory in Cambridge, United Kingdom. NeoGenomics also has
several, small, non-processing laboratory locations across the
United States for providing analysis services. NeoGenomics serves
the needs of pathologists, oncologists, academic centers, hospital
systems, pharmaceutical firms, integrated service delivery
networks, and managed care organizations throughout the United
States, and pharmaceutical firms in Europe and Asia.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240923921828/en/
Investor Contact Kendra Sweeney
kendra.sweeney@neogenomics.com
Media Contact Andrea Sampson
asampson@sampsonprgroup.com
NeoGenomics (NASDAQ:NEO)
Historical Stock Chart
From Nov 2024 to Dec 2024
NeoGenomics (NASDAQ:NEO)
Historical Stock Chart
From Dec 2023 to Dec 2024